Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Lymphocytic Leukaemia (CLL): Update Bulletin [May 2017]

Product Code:
596200629
Publication Date:
May 2017
Format:
PDF
Price:
€1265

Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of Chronic Lymphocytic Leukaemia (CLL). Coverage includes KOL opinions about the Phase III results published from the GENUINE study investigating TG Therapeutics’ novel anti-CD20 monoclonal antibody (mAb) in combination with J&J/AbbVie’s Imbruvica (ibrutinib). Topics covered include KOL opinions on the approval of Celltrion/Mundipharma biosimilar rituximab (Truxima) by the European Commission. KOLs also provide their candid insights on the sequencing of novel targeted therapies in CLL, availability of real-world data and the future of chemotherapies.

  • How do KOLs view the recent Phase III study results of TG Therapeutics’ ublituximab in combination with ibrutinib in the GENUINE trial?
  • How do KOLs compare the combination of ibrutinib with ublituximab over the combination of ibrutinib with rituximab and over ibrutinib monotherapy?
  • In what type of patients will KOLs use the combination of ublituximab and ibrutinib, if approved?
  • Will KOLs require clinical studies to demonstrate the similarity of Truxima to rituximab in CLL? If so, what studies are required?
  • How comfortable are KOLs in extrapolating data for the use of Truxima in non-Hodgkin lymphoma (NHL) to CLL?
  • Will cost pressures force KOLs to adopt Truxima in patients that require rituximab?
  • How will Truxima impact the usage of other anti-CD20 drugs in CLL treatment?
  • What are KOL opinions about real-world studies to determine sequencing of treatments in CLL patients? Are there any drawbacks of the current real-world sequencing studies?
  • How do KOLs feel about the continued use of chemotherapy in the treatment of patients with CLL?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved